- ADVANZ PHARMA and Endo Announce Partnership for Paladin Labs to Commercialize Xydalba® (dalbavancin hydrochloride) in Canada
- Endo Comments on Entry of Default Liability Judgment in Tennessee State Court Case
- Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes
- Endo International plc Announces Proposed Private Offering Of Senior Secured Notes
- Endo International plc Commences Refinancing of its Existing Term Loan
- Endo Reports Fourth-Quarter And Full-Year 2020 Financial Results And Introduces 2021 Financial Guidance
- Endo to Participate at J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference
- Endo Appoints Jennifer M. Chao to Board of Directors
- Endo to Announce Fourth-Quarter and Full-Year 2020 Financial Results
Endo International PLC (EO7:STU) closed at 5.08, 127.89% above the 52 week low of 2.23 set on Sep 11, 2020.
2.23Sep 11 20209.15Feb 19 2021
Markit short selling activity
|Market cap||1.42bn USD|
|EPS (TTM)||0.5015 |
Data delayed at least 15 minutes, as of Apr 12 2021.